# Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs’ Effects: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/development-of-cancer-drugs-for-use-in-novel-combination-determining-the-contribution-of-the-individual-drugs-effects-draft-guidance-for-industry/bd360fda-a944-4c60-9940-379a8b849635

> FDA guidance document: Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs’ Effects: Draft Guidance for Industry. Issue date: July 17, 2025. Get complete insights and analysis.

---

## Details

- Title: Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs’ Effects: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2025-07-17
- Comment Close Date: 2025-09-15
- Last Changed: 2025-07-16
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2025-D-1071">FDA-2025-D-1071</a>

## Related Documents

- [Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry/3835823e-c995-46e5-98c7-9422ad94971f)
- [Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-generating-clinical-evidence-from-oncology-multiregional-clinical-development-programs/78fa8deb-dab7-4321-a08d-f5971e107619)
- [Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document](https://www.globalkeysolutions.net/guidances/guidance-document/combined-food-and-drug-administration-and-sponsor-oncologic-drugs-advisory-committee-briefing-document/acf14472-e5b8-47ba-a5bd-76d6bae8bd27)